For education only · Not medical advice
← All articles
October 2026 Cognitive & Sleep 7 min read

Cerebrolysin: a porcine brain extract with real trials

Cerebrolysin is the most unusual molecule in the cognitive peptide world because it is not a molecule at all but a mixture of hundreds of peptides digested out of pig brain, approved in dozens of countries, and backed by a randomized trial program large enough that independent reviewers have been able to disagree with the manufacturer in detail.

The short answer

  • Cerebrolysin is not a single peptide. It is a solution of low-molecular-weight peptides and free amino acids made by enzymatically digesting pig brain proteins.
  • It is Approved in Austria and reportedly 40 to 50 other countries, mostly Eastern Europe, Russia and parts of Asia, for stroke, traumatic brain injury and dementia. Not FDA approved, no Canadian DIN, as of September 2026.
  • It sits at Human trials for stroke, post-stroke rehabilitation, traumatic brain injury, vascular dementia and Alzheimer’s disease, and at Preclinical only for cognitive enhancement in healthy people.
  • The independent Cochrane review of acute stroke found it probably does not reduce death, and may increase non-fatal serious adverse events.
  • Manufacturer-funded trials in early rehabilitation report modest benefits, and a 2021 European guideline recommends it there. Both readings rest on real data.

What is actually in the vial

Cerebrolysin, development code FPF-1070, is made by controlled enzymatic digestion of porcine brain protein. The injectable solution contains 215.2 mg/mL of what the label calls Cerebrolysin concentrate. There is no single sequence and no identified active moiety.

The most useful analytical work came from an unexpected direction. Researchers bought a sample over the internet and ran it through mass spectrometry, identifying 638 distinct peptides, mostly fragments of tubulin, actin and myelin basic protein (Gevaert 2015). They found no fragments of the neurotrophic factors the product’s mechanism story is built around: no GDNF, NGF, BDNF or CNTF. Any activity, the authors suggested, would have to come from uncharacterised “cryptic” peptides.

That matters for how you read mechanism claims. Cerebrolysin is routinely described as having neurotrophic, anti-apoptotic and anti-excitotoxic activity based on cell and animal models. Whether meaningful quantities of active peptides cross the human blood-brain barrier after an infusion has never been directly measured, and no human study ties a specific peptide or pathway to a clinical outcome. Pharmacokinetics are not characterisable in the conventional sense: you cannot track hundreds of peptides as one analyte, and no validated marker of exposure exists.

The stroke evidence, both readings

This is worth understanding properly, because it is a clean example of two competent groups reading the same field differently.

The independent reading. The 2023 Cochrane review pooled 7 randomized trials and 1,773 participants given Cerebrolysin within 48 hours of an ischaemic stroke. All-cause death: relative risk 0.96 (95% CI 0.65 to 1.41), moderate certainty, so probably no effect. Total serious adverse events: RR 1.16. Non-fatal serious adverse events: increased, RR 2.39 (1.10 to 5.23), and more marked at 30 mL daily for 10 days, where RR was 2.87. No trial reported the composite of death or dependence, the outcome that matters most to a stroke patient. Risk of bias was mostly unclear, and the manufacturer supported three of the multicentre trials.

Two trials are worth naming. CASTA randomized 1,070 patients to 30 mL intravenously daily for 10 days starting within 12 hours, and was neutral on its primary endpoint, with a post-hoc trend in more severe strokes (Heiss 2012). CERE-LYSE gave 119 patients Cerebrolysin one hour after alteplase and stopped at interim analysis for no 90-day modified Rankin benefit, though the combination was safe (Lang 2013).

The manufacturer-linked reading. In early post-stroke rehabilitation, started 24 to 72 hours after the event and paired with standardised physiotherapy, the picture looks better. The CARS trial used 30 mL daily for 21 days and reported a large effect on the Action Research Arm Test at day 90, though its own authors called it exploratory and asked for a confirmatory trial (Muresanu 2016). Pooling CARS-1 and CARS-2 across 442 patients kept the signal, and a nine-trial meta-analysis found an effect on early NIHSS change. A 2021 European Academy of Neurology and EFNR guideline recommends 30 mL daily intravenously for at least 10 days in early neurorehabilitation (Beghi 2021), and a manufacturer-affiliated safety meta-analysis of 12 neurorecovery trials in 2,202 patients found no significant excess of adverse events.

Why they differ. Different inclusion windows, different outcomes, and crucially different statistics: the positive analyses lean on multivariate Wei-Lachin ensembles built from 13 or 14 scales, hard to translate into patient-level benefit, while Cochrane used conventional binary outcomes. Several guideline and meta-analysis authors were trial investigators or manufacturer consultants. A reasonable synthesis: Cerebrolysin does not save lives in acute stroke, and a modest effect on early motor recovery is possible but rests mainly on manufacturer-run trials with unconventional endpoints.

Traumatic brain injury and dementia

TBI. CAPTAIN I enrolled 46 patients and missed its primary multivariate endpoint in the intention-to-treat analysis, reaching significance only per protocol. CAPTAIN II analysed 139 patients at one centre and reported a small-to-medium effect at day 90. Small trials, manufacturer-linked, composite endpoints.

Vascular dementia. A separate Cochrane review pooled 6 trials and 597 participants, mostly from China, Russia and Romania. Cognition improved (standardised mean difference 0.36) and global response RR was 2.69, but both were graded very low certainty and the authors judged the data not definitive (Cui 2019).

Alzheimer’s disease. A meta-analysis of 6 trials at 30 mL daily reported cognitive benefit at 4 weeks and global benefit at 6 months (Gauthier 2015). Its co-authors include a manufacturer employee and its biometric consultant, and no independent confirmatory trial exists.

Cognitive enhancement in healthy people. No controlled trials at all: Preclinical only. That is the tier that matters most to anyone reading about Cerebrolysin as a nootropic.

Dose, route and the grey-market problem

Label doses exist because the product is approved somewhere, so they can be stated plainly. Per the manufacturer’s 2023 treatment handbook, with national labels varying: stroke, 20 to 50 mL daily for 10 to 21 days; traumatic brain injury, 20 to 50 mL daily for 7 to 30 days; Alzheimer’s disease and vascular dementia, 10 to 30 mL daily in cycles of 5 days per week for 4 weeks. Administration is intravenous infusion diluted into at least 100 mL of saline, Ringer’s or 5% glucose, or intramuscular injection up to 5 mL. Ampoules are single use and must be used immediately after opening, because microbial contaminants can grow in the solution. Trials mostly used 30 mL daily for 10 to 21 days.

What circulates online is different and has no evidence behind it: small intramuscular or subcutaneous volumes in self-administered nootropic cycles, sometimes drawn repeatedly from one opened ampoule. No trial has studied low-volume intramuscular or subcutaneous dosing for cognitive enhancement, and reusing an opened ampoule contradicts the sterility instruction. Authenticity of internet-sourced product is unknown, which is what Gevaert’s group was investigating.

Safety and the things people forget

Overall adverse event rates in trials were similar to placebo, but the Cochrane non-fatal serious adverse event signal is real. The manufacturer’s documents describe infusion-related excitability, advising morning dosing after the first dose, plus fever, and tachycardia, blood pressure rise and arrhythmia if administration is too fast. Contraindications include hypersensitivity, severe renal impairment at GFR categories G4 and G5, and epilepsy, though the handbook is internally inconsistent, naming only status epilepticus in one list. Additive effects with antidepressants and MAO inhibitors are noted, and high-dose MAO inhibitors with 30 mL or more have been reported to raise blood pressure.

Two points get overlooked. First, the source is porcine, which is relevant to pork allergy, to theoretical alpha-gal sensitisation, and to anyone who avoids pork for religious or dietary reasons. Animal-derived material also carries a theoretical adventitious-agent risk that depends on manufacturing controls, which grey-market supply does not provide. Second, anything that makes a person feel sharper can delay a diagnosis of sleep apnoea, thyroid disease, depression or early dementia. For the wider framing, see how peptides work in the body and /start-here.

As of September 2026: not FDA approved, and not on FDA’s 503A Category 1, 2 or withdrawn lists (page current 22 April 2026). No Health Canada DIN, so importing or selling it for human use in Canada is unauthorized. It is not named on the 2026 WADA Prohibited List, and because it is approved in several countries the catch-all S0 category does not apply; whether S2.3 could be argued has not been tested, so a tested athlete should get a written ruling first. One honesty note: the commonly cited country count, between 44 and “more than 50”, could not be verified against a primary regulator list.

The bottom line

Cerebrolysin is the instructive exception in the cognitive peptide field: the evidence exists, which is precisely why it can be judged, and independent and manufacturer-linked reviewers have judged it differently. It probably does not reduce death in acute stroke and may raise non-fatal serious adverse events; a modest early motor rehabilitation effect is plausible but not independently confirmed. For healthy people buying ampoules online, there is no trial evidence, a route nobody studied, and a sterility instruction being ignored.

Education only. This page is educational. Most compounds referenced are not approved for human use, and a “research use only” label carries no legal status of its own. Nothing here constitutes medical advice, diagnosis, or treatment.

Sources

Peptides 101CognitionEvidence Tiers
For education only · Not medical advice